Aptevo Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Aptevo Therapeutics has a total shareholder equity of $4.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.1M and $10.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.75m |
| Equity | US$4.42m |
| Total liabilities | US$10.73m |
| Total assets | US$15.15m |
Recent financial health updates
Recent updates
Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy
Sep 19Aptevo meets primary endpoint in early-stage trial for blood cancer therapy
May 26Aptevo: Positive Early Stage Data Makes This Highly Interesting
Dec 02Aptevo gets $50/share takeout offer from shareholder Tang
Nov 18Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
Nov 09Aptevo sells off after clarifying complete response in early-stage study on lead drug
Nov 05Financial Position Analysis
Short Term Liabilities: APVO's short term assets ($10.0M) exceed its short term liabilities ($5.9M).
Long Term Liabilities: APVO's short term assets ($10.0M) exceed its long term liabilities ($4.8M).
Debt to Equity History and Analysis
Debt Level: APVO is debt free.
Reducing Debt: APVO has no debt compared to 5 years ago when its debt to equity ratio was 99.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APVO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: APVO has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.6% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 15:33 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aptevo Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangzhi Li | Ladenburg Thalmann & Company |
| Edward Tenthoff | Piper Sandler Companies |
| Jonathan Aschoff | Roth MKM |